LIN37 is a component of the DREAM complex, a multiprotein entity that plays a critical role in the regulation of cell cycle progression and gene expression. By participating in the assembly of the DREAM complex, LIN37 contributes to the repression of a wide array of genes during the G0 and early G1 phase of the cell cycle, effectively coordinating cellular quiescence with the molecular machinery responsible for cell cycle control. This regulatory function underscores the importance of LIN37 in maintaining cellular homeostasis, ensuring that cells only proceed to divide when appropriate signals and conditions are present. Beyond cell cycle regulation, LIN37 is implicated in various processes related to DNA damage response, differentiation, and development, highlighting its versatility and significance in cellular physiology.
The inhibition of LIN37, and consequently the disruption of the DREAM complex's function, can occur through several mechanisms, each affecting the complex's ability to regulate gene expression and control cell cycle progression. One such mechanism involves the direct binding of inhibitory proteins or small molecules to LIN37, altering its conformation or its ability to interact with other components of the DREAM complex. This disruption can lead to the deregulation of genes that are normally repressed by the DREAM complex, potentially resulting in uncontrolled cell proliferation or the failure to respond appropriately to DNA damage. Another mechanism of LIN37 inhibition includes changes in post-translational modifications, such as phosphorylation or ubiquitination, which may affect LIN37's stability, localization, or interaction with other proteins. Furthermore, the transcriptional downregulation of LIN37 through signaling pathways or transcription factors that suppress its expression can significantly impact the assembly and function of the DREAM complex. These mechanisms highlight the critical balance required for LIN37 function and the potential consequences of its inhibition on cell cycle regulation and cellular homeostasis.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Inhibits CDK4/6, leading to G1 phase arrest and potentially disrupting LIN37's role in the DREAM complex. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Selectively inhibits CDK4/6, similar to Palbociclib, possibly affecting LIN37 functionality. | ||||||
Abemaciclib | 1231929-97-7 | sc-507342 | 10 mg | $110.00 | ||
CDK4/6 inhibitor that may interfere with LIN37's interaction with cell cycle regulators. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Inhibits CDKs, possibly altering the phosphorylation status of proteins in LIN37-mediated pathways. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Inhibits CDKs and could disrupt the phosphorylation of LIN37's partners in the DREAM complex. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Another CDK inhibitor that can affect the cell cycle and potentially LIN37's associated processes. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Inhibits CDK1/cyclin B, which might affect the DREAM complex activity and therefore LIN37. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $72.00 $297.00 | 4 | |
Targets CDKs and may influence the cell cycle phases where LIN37 is involved. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
Strong CDK inhibitor with the potential to disrupt LIN37's interaction with cell cycle proteins. | ||||||
SNS-032 | 345627-80-7 | sc-364621 sc-364621A | 5 mg 10 mg | $169.00 $262.00 | ||
A potent CDK inhibitor that could alter the activity of LIN37's protein complex. | ||||||